The Effects of Exenatide (Byetta ) on Energy Expenditure and Weight Loss in Nondiabetic Obese Subjects
Status:
Completed
Trial end date:
2016-09-19
Target enrollment:
Participant gender:
Summary
Exenatide is an incretin-like drug that has been approved for treatment of type 2 diabetes;
it improves glycemia by increasing insulin and decreasing glucagon secretion by pancreatic
islet cells and delaying gastric emptying. This randomized, placebo-controlled study is to
evaluate whether exenatide over a 5 week period in non-diabetic obese subjects may lead to
weight loss. To control for variability in individual response to weight loss treatment, this
study will assess the role of exenatide in changing food intake and energy expenditure as
possible sources of weight loss. This study will also evaluate the safety profile of
exenatide in non-diabetic obese people. Additional assessments will evaluate changes in body
fat and hormones involved in the sensations of hunger and fullness.
Phase:
Phase 3
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)